Company: CI
Filing Date: 2025-05-02
Form Type: 10-Q
Source: 0001739940-25-000021
Chunk: 258

Company: Cigna Group
Filing Date: 2025-05-02
Form: 10-Q
Item: Part II, Item 15
Chunk 258
---
AP basis)Three Months Ended March 31,(Dollars in millions)20252024ChangePharmacy revenues$48,633 $42,036 16 %Premiums12,736 11,603 10 Fees and other revenues3,895 3,326 17 Net investment income238 290 (18)Total revenues65,502 57,255 14 Pharmacy and other service costs48,398 41,431 17 Medical costs and other benefit expenses10,498 9,440 11 Selling, general and administrative expenses4,213 3,705 14 Amortization of acquired intangible assets422 423 — Total benefits and expenses63,531 54,999 16 Income from operations1,971 2,256 (13)Interest expense and other(362)(322)12 Gain (loss) on sale of businesses41 (19)N/MNet investment losses(2)(1,836)(100)Income before income taxes1,648 79 N/MTotal income taxes239 291 (18)Net income (loss)1,409 (212)N/MLess: Net income attributable to noncontrolling interests86 65 32 Shareholders' net income (loss)$1,323 $(277)N/M%Consolidated effective tax rate14.5 %368.4 %N/MbpsMedical customers (in thousands)18,043 19,184 (6)%

31

Reconciliation of Shareholders' Net Income (Loss) (GAAP) to Adjusted Income from OperationsThree Months Ended March 31,20252024(In millions)Pre-taxAfter-taxPre-taxAfter-taxShareholders' net income (loss)$1,323 $(277)Adjustments to reconcile to adjusted income from operationsNet investment (gains) losses (1)$(48)(48)$1,828 1,827 Amortization of acquired intangible assets422 336 423 322 Special itemsIntegration and transaction-related costs216 164 37 29 Strategic optimization program215 163 — — Deferred tax expenses, net (2)— 17 — 17 (Gain) loss on sale of businesses (41)(115)19 (43)Total special items$390 229 $56 3 Adjusted income from operations$1,840 $